Main clinical study
In our pivotal head-to-head study, RISE-PD, CREXONT gave people more “Good On” time with less frequent dosing compared to IR CD/LD*
Main clinical study
What is RISE-PD?
RISE-PD is a Phase 3, double-blind, head-to-head study that helped support FDA approval of CREXONT by exploring its benefits in people taking CREXONT compared to people taking IR CD/LD.
*“Good On” time is defined as “On” time without troublesome dyskinesia.
More “Good On” time
Explore the benefits of CREXONT
Explore the benefits of CREXONT
MAIN MEASUREMENT
compared with IR CD/LD
†“Good On” time is defined as “On” time without troublesome dyskinesia. Change in “Good On” time was measured by comparing values at the end of study to baseline; P=0.019 vs IR CD/LD.
‡This was the average dose frequency during the double-blind maintenance period.
SECONDARY MEASUREMENT
compared with IR CD/LD
§This was a secondary endpoint of the study.
¶Study end=Week 20 or early termination; P=0.025 vs IR CD/LD.
A DIFFERENT ANALYSIS OF THE SAME STUDY
compared with IR CD/LD
#“Good On” time is defined as “On” time without troublesome dyskinesia.
||This was a post hoc analysis of the study; P<0.0001 vs IR CD/LD.
MAIN MEASUREMENT
In our main clinical study, people who took CREXONT an average of 3 times a day achieved 30 minutes more “Good On” time per day than those taking IR CD/LD an average of 5 times a day
†“Good On” time is defined as “On” time without troublesome dyskinesia. Change in “Good On” time was measured by comparing values at the end of study to baseline; P=0.019 vs IR CD/LD.
‡This was the average dose frequency during the double-blind maintenance period.
SECONDARY MEASUREMENT
People who took CREXONT had 30 minutes less “Off” time per day compared with those who took IR CD/LD
§This was a secondary endpoint of the study.
¶Study end=Week 20 or early termination; P=0.0252 vs IR CD/LD.
People who took CREXONT had 30 minutes less “Off” time per day compared with those who took IR CD/LD
A DIFFERENT ANALYSIS OF THE SAME STUDY
In a different analysis of our main clinical study of a dose-to-dose comparison, people took CREXONT fewer times per day and experienced over an hour and a half more “Good On” time per dose than people taking IR CD/LD
#“Good On” time is defined as “On” time without troublesome dyskinesia.
||This was a post hoc analysis of the study; P<0.0001 vs IR CD/LD.
In a different analysis of our main clinical study of a dose-to-dose comparison, people took CREXONT fewer times per day and experienced over an hour and a half more “Good On” time per dose than people taking IR CD/LD
